Adam’s Biotech Scorecard :Profiting from ‘legal’ insider trading isn’t always easy

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Last night, we held our 2024 STATUS List dinner, honoring 50 influential people shaping the future of health, medicine and life sciences. It was an amazing evening, and a chance to eat and chat with some brilliant and engaging honorees. At dinner, to my left, was Biogen CEO Chris Viehbacher; to my right, Avoro Capital’s Behzad Aghazadeh. I sat directly across from Novo Nordisk scientist Lotte Knudsen. AstraZeneca’s cancer R&D chief Susan Galbraith and Harvard’s sickle cell scientist Stuart Orkin were nearby. Incredible. The chicken was delicious.

This week, I crunched some performance numbers for biotech PIPES, and chatted with the CEO of Benitec Biopharma about its gene therapy for a rare genetic disorder that weakens muscles around the throat. Plus, biotech watercooler updates on Vera Therapeutics and Biohaven Pharma. As always, send feedback and questions to [email protected]